Chemorefractory liver metastasis from cervical cancer successfully treated with a combination of yttrium-90 and immunotherapy.

Abstract

Liver metastases in cervical cancer is rare and can be difficult-to-treat. The current guidelines established by the Gynecologic Oncology Group recommend platinum-based systemic chemotherapy in combination with an anti-angiogenic agent such as bevacizumab, however, overall survival remains poor following diagnosis and options for patients who fail chemotherapy are limited. Yttrium-90 (Y90) radioembolization (RE) has shown great promise in the treatment of chemo-refractory colorectal liver metastases. We describe a 30-year-old female with a history of stage IB endocervical adenocarcinoma who later developed metastases to the liver, that were unresponsive to multiple chemotherapeutics and chemoembolization, and was successfully treated with Y90 RE with concurrent systemic Pembrolizumab. The Y90 RE treatment resulted in positive clinical and imaging responses with improvement in her quality of life, all of which continue to persist at the time of writing this manuscript about 8-months into her RE treatment.

• Authors: Michael E Nance, Gregory B Biedermann, Ambarish P Bhat, Ryan M Davis
• Journal: Radiology case reports (Radiol Case Rep) Vol. 15 Issue 8 Pg. 1359-1365 (Aug 2020) ISSN: 1930-0433 [Print] Netherlands
• PMID: 32636973 (Publication Type: Case Reports)
• Copyright: © 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington.